Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 16,059,540 | 15,834,110 | 14,884,170 | 13,482,890 | 12,400,060 |
| Cost of Goods | 2,408,774 | 2,596,405 | 2,518,334 | 2,326,752 | 2,352,880 |
| Gross Profit | 13,650,760 | 13,237,710 | 12,365,840 | 11,156,140 | 10,047,180 |
| Operating Expenses | 6,294,270 | 7,088,186 | 6,757,271 | 6,063,785 | 5,866,350 |
| Operating Income | 7,357,267 | 6,149,924 | 5,608,903 | 5,093,107 | 4,181,710 |
| Interest Expense | 899,645 | 100,383 | 116,834 | 308,966 | 0 |
| Other Income | 12,649 | 29,776 | 303,127 | 21,600 | -83,930 |
| Pre-tax Income | 6,470,271 | 6,079,317 | 5,795,196 | 4,805,741 | 4,097,780 |
| Income Tax | 1,283,102 | 1,357,755 | 1,309,926 | 1,102,291 | 902,350 |
| Net Income Continuous | 5,187,168 | 4,721,563 | 4,485,271 | 3,703,449 | 3,030,153 |
| Net Income | $5,187,168 | $4,721,563 | $4,485,271 | $3,703,449 | $3,195,420 |
| EPS Basic Total Ops | 1.01 | 0.90 | 0.84 | 0.68 | 0.54 |
| EPS Basic Continuous Ops | 1.01 | 0.90 | 0.84 | 0.68 | 0.54 |
| EPS Diluted Total Ops | 1.01 | 0.90 | 0.83 | 0.67 | 0.53 |
| EPS Diluted Continuous Ops | 1.01 | 0.90 | 0.83 | 0.67 | 0.53 |
| EBITDA(a) | $7,797,568 | $6,762,384 | $6,107,404 | $5,558,458 | $4,181,710 |